VNN1

Across TCGA pan-cancer cohorts, VNN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VNN1 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher VNN1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated VNN1 expression acts as an unfavorable survival marker, although some lineages such as OV and SCLC show a favorable association.

OV, LUSC, and GBM are the cancer types where VNN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	III,IV	1.000	0.149	.017	12	view →
LUSC	OS	Median	III,IV	0.146	0.690	<.001	12	view →
GBM	DFS	Median	All	0.058	0.258	.008	6	view →
LUAD	OS	Median	All	0.331	0.837	<.001	6	view →
SCLC	DFS	Median	II,III,IV	1.000	0.308	.038	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VNN1–OV (DFS)

Open the OV breakdown →